NHC
IDXX icon

Nicholas Hoffman & Company’s Idexx Laboratories IDXX Stock Holding History

Nicholas Hoffman & Company’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-387
Closed -$262K – 336
2025
Q4 		$262K Sell
387
-11
-3% -$7.49K 0.01% 289
2025
Q3 		$254K Buy
+398
New +$242K 0.01% 279

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nicholas Hoffman & Company's IDXX Position: Q1 2026 in Review

Nicholas Hoffman & Company sold out of Idexx Laboratories (IDXX) in Q1 2026, closing a stake of 387 shares — an estimated $262K sold.

Nicholas Hoffman & Company first reported a position in IDXX in Q3 2025 and held it in 2 quarters. The position peaked at $262K in Q4 2025. 1,314 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Nicholas Hoffman & Company reported no remaining Idexx Laboratories position as of Q1 2026 after selling out during the quarter.
  • Nicholas Hoffman & Company sold 387 Idexx Laboratories shares in Q1 2026, an estimated $262K.
  • Nicholas Hoffman & Company first reported a position in Idexx Laboratories in Q3 2025 and held it in 2 quarters.
  • Nicholas Hoffman & Company's Idexx Laboratories position peaked at $262K in Q4 2025.
  • 1,314 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Nicholas Hoffman & Company's 13F filing for Q1 2026, filed 29 Apr 2026.